|
|
| (41 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | *'''[[Unproven ideas]]'''
| |
| − | *'''[[Reviews on covid19 disease]]'''
| |
| | | | |
| | | | |
| | + | *'''[[Unproven ideas]]''' |
| | | | |
| | + | *'''[[Reviews on covid19 disease]]''' |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| | | | |
| | | | |
| | + | *'''[[Respiration mgmt]]''' |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| Zeile 23: |
Zeile 20: |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | *'''[[Target binding and uptake]]'''
| |
| | | | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| Zeile 41: |
Zeile 38: |
| | | | |
| | | | |
| − | ----
| + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| − |
| |
| | | | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | | | |
| | | | |
| Zeile 58: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32339350|t=2020. COVID-19 associated pulmonary aspergillosis |pdf=|usr=}}
| |
| − | {{tp|p=32379193|t=2020. A CASE OF CHILDHOOD COVID-19 INFECTION WITH PLEURAL EFFUSION COMPLICATED BY POSSIBLE SECONDARY MYCOPLASMA PNEUMONIAE INFECTION |pdf=|usr=}}
| |
| − | {{tp|p=32287051|t=2020. Coinfection of Influenza Virus and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32376725|t=2020. Co-infection and Other Clinical Characteristics of COVID-19 in Children |pdf=|usr=}}
| |
| − | {{tp|p=32238260|t=2020. Coinfeccion entre dengue y COVID-19: Necesidad de abordaje en zonas endemicas |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32367765|t=2020. Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count |pdf=|usr=}}
| + | |
| − | {{tp|p=32367749|t=2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32376225|t=ä. Pulmonary embolism in COVID-19 When nothing is what it seems |pdf=|usr=}}
| + | |
| − | {{tp|p=32324101|t=2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands |pdf=|usr=}}
| + | |
| − | {{tp|p=32324103|t=2020. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography |pdf=|usr=}}
| + | |
| − | {{tp|p=32324102|t=2020. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels |pdf=|usr=}}
| + | |
| − | {{tp|p=32324099|t=2020. Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32374544|t=2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives |pdf=|usr=}}
| + | |
| − | {{tp|p=32378030|t=ä. COVID-19-Related Stroke |pdf=|usr=}}
| + | |
| − | {{tp|p=32279286|t=2020. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring |pdf=|usr=}}
| + | |
| − | {{tp|p=32349133|t=2020. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge |pdf=|usr=}}
| + | |
| − | {{tp|p=32349132|t=2020. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?|pdf=|usr=}}
| + | |
| − | {{tp|p=32316065|t=2020. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines |pdf=|usr=}}
| + | |
| − | {{tp|p=32316063|t=2020. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure |pdf=|usr=}}
| + | |
| − | {{tp|p=32374920|t=2020. Viscoelastic testing in COVID-19: a possible screening tool for severe disease?|pdf=|usr=}}
| + | |
| − | {{tp|p=32220276|t=2020. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia |pdf=|usr=}}
| + | |
| − | {{tp|p=32133825|t=2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32133824|t=2020. COVID-19 complicated with DIC: 2 cases report and literatures review |pdf=|usr=}}
| + | |
| − | {{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32366611|t=2020. Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia |pdf=|usr=}}
| |
| − | {{tp|p=32145715|t=2020. A case report of aplastic anemia accompanied with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32141280|t=2020. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32129583|t=2020. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics |pdf=|usr=}}
| |
| − | {{tp|p=32118392|t=2020. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations |pdf=|usr=}}
| |
| − | {{tp|p=32118393|t=2020. Myocardial injury in patients with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32171190|t=2020. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32347088|t=2020. Effects of novel coronavirus therapeutic drugs on cardiovascular system |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32380269|t=ä. The COVID-19 pandemic: consideration for brain infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32379311|t=ä. Letter: Anosmia in COVID-19: Severe Acute Respiratory Syndrome Coronavirus 2 Through the Nasoliary Epithelium and a Possible Spreading Way to the Central Nervous System?A Purpose to Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32358218|t=2020. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy |pdf=|usr=}}
| + | |
| − | {{tp|p=32345728|t=2020. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32327489|t=2020. Neurologic manifestations in an infant with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32303650|t=2020. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333489|t=2020. Is gustatory impairment the first report of an oral manifestation in COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32369434|t=2020. Acute Parotitis: A Possible Precocious Clinical Manifestation of SARS-CoV-2 Infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32369429|t=2020. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32366195|t=2020. Anosmia and the Need for COVID-19 Screening during the Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32366161|t=2020. Olfactory Dysfunction in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32366160|t=2020. Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19 With Public Health Significance |pdf=|usr=}}
| + | |
| − | {{tp|p=32340555|t=2020. COVID-19 Anosmia Reporting Tool: Initial Findings |pdf=|usr=}}
| + | |
| − | {{tp|p=32366595|t=2020. Acute anosmia from COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32228363|t=2020. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features |pdf=|usr=}}
| + | |
| − | {{tp|p=32338254|t=2020. Olfactory and rhinological evaluations in SARS-CoV-2 patients complaining of olfactory loss |pdf=|usr=}}
| + | |
| − | {{tp|p=32319971|t=2020. Anosmia as a prominent symptom of COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32240279|t=2020. Isolated sudden onset anosmia in COVID-19 infection A novel syndrome?|pdf=|usr=}}
| + | |
| − | {{tp|p=32277751|t=2020. Presentation of new onset anosmia during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32320129|t=2020. Explanation for COVID-19 infection neurological damage and reactivations |pdf=|usr=}}
| + | |
| − | {{tp|p=32220634|t=2020. Sars-Cov-2: Underestimated damage to nervous system |pdf=|usr=}}
| + | |
| − | {{tp|p=32316719|t=2020. Expression analysis of 2019-nCoV related ACE2 and TMPRSS2 in eye tissues |pdf=|usr=}}
| + | |
| − | {{tp|p=32306616|t=2020. Strengthening basic and clinical research on ocular infection caused by coronavirus |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32369674|t=2020. Oral vesiculobullous lesions associated with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32374033|t=2020. Chilblains-like lesions in children following suspected Covid-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32315079|t=2020. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32367837|t=2020. Gastrointestinal and liver manifestations of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32369476|t=2020. Sintomas digestivos en la enfermedad por coronavirus 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32153170|t=2020. Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region |pdf=|usr=}}
| |
| − | {{tp|p=32270660|t=2020. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area |pdf=|usr=}}
| |
| − | {{tp|p=32077660|t=2020. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study |pdf=|usr=}}
| |
| − | {{tp|p=32077659|t=2020. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32075364|t=2020. Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| − | {{tp|p=32249664|t=2020. Focus on the Crosstalk Between COVID-19 and Urogenital Systems |pdf=|usr=}}
| |
| − | {{tp|p=32365180|t=ä. Potential influence of COVID-19/ACE2 on the female reproductive system |pdf=|usr=}}
| |
| − | {{tp|p=32340507|t=2020. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32348049|t=2020. Vue sur le COVID-19 depuis la nephrologie |pdf=|usr=}}
| |
| − | {{tp|p=32145717|t=2020. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32281287|t=2020. Risk of COVID?19 for patients with obesity |pdf=|usr=}}
| |
| − | {{tp|p=32237212|t=ä. COVID 19 and the Patient with Obesity ? The Editors Speak Out |pdf=|usr=}}
| |
| − | {{tp|p=32332320|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32250049|t=ä. COVID?19 infection in a paucisymptomatic infant: Raising the index of suspicion in epidemic settings |pdf=|usr=}}
| |
| − | {{tp|p=32365269|t=2020. Obesity and severe COVID-19 disease: a strong association |pdf=|usr=}}
| |
| − | {{tp|p=32365275|t=2020. Obesity accompanying COVID-19: the role of epicardial fat |pdf=|usr=}}
| |
| − | {{tp|p=32352637|t=2020. Association of Obesity with Disease Severity among Patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339391|t=2020. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections |pdf=|usr=}}
| |
| − | {{tp|p=32324968|t=2020. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32314871|t=2020. Targeting the Adipose Tissue in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32314868|t=2020. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?|pdf=|usr=}}
| |
| − | {{tp|p=32314861|t=2020. Obesity is Associated with Severe Forms of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32286926|t=2020. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths?|pdf=|usr=}}
| |
| − | {{tp|p=32319118|t=2020. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover |pdf=|usr=}}
| |
| − | {{tp|p=32366612|t=2020. Early Neonatal SARS-CoV-2 Infection Manifesting With Hypoxemia Requiring Respiratory Support |pdf=|usr=}}
| |
| − | {{tp|p=32345686|t=2020. Vulnerable Youth and the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32317311|t=2020. Mitigating the Impacts of the COVID-19 Pandemic Response on At-Risk Children |pdf=|usr=}}
| |
| − | {{tp|p=32339304|t=2020. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression |pdf=|usr=}}
| |
| − | {{tp|p=32234837|t=2020. COVID-19 and non-communicable diseases |pdf=|usr=}}
| |
| − | {{tp|p=32304114|t=2020. Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission |pdf=|usr=}}
| |
| − | {{tp|p=32377638|t=2020. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32319449|t=2020. A pregnant woman and the SARS-CoV-2 infection: how are barriers easily crossed?|pdf=|usr=}}
| |
| − | {{tp|p=32374541|t=2020. Diabete et infection a COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348046|t=2020. Rhumatologie et COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348045|t=2020. Maladies autoimmunes dans le contexte de la pandemie COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348044|t=2020. L'hematologie au temps du COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348042|t=2020. Infection a SARS-CoV-2 et transplantation d'organes solides |pdf=|usr=}}
| |
| − | {{tp|p=32301198|t=ä. Case report: A kidney transplant patient with mild COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32160345|t=ä. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals |pdf=|usr=}}
| |
| − | {{tp|p=32302282|t=2020. Sex- and Gender-specific Observations and Implications for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364677|t=2020. COVID-19 pneumonia in kidney transplant recipients-Where we are?|pdf=|usr=}}
| |
| − | {{tp|p=32279418|t=2020. Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32357273|t=2020. A catabolic state in a kidney transplant recipient with COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32180292|t=2020. Coronavirus in pregnancy and delivery: rapid review |pdf=|usr=}}
| |
| − | {{tp|p=32266753|t=2020. Intrauterine vertical transmission of SARS-CoV-2: what we know so far |pdf=|usr=}}
| |
| − | {{tp|p=32349165|t=2020. Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32304612|t=2020. Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32135587|t=2020. 2019 novel coronavirus infection in a three-month-old baby |pdf=|usr=}}
| |
| − | {{tp|p=32234132|t=2020. First case of neonate with COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32268709|t=2020. Attach importance to COVID-19 infection on maternal and infant outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32145714|t=2020. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province |pdf=|usr=}}
| |
| − | {{tp|p=32164092|t=2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32340096|t=2020. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension |pdf=|usr=}}
| |
| − | {{tp|p=32283876|t=2020. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32189489|t=2020. ACE2 in the context of 2019-nCoV infection: friend or foe? |pdf=|usr=}}
| |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32164083|t=2020. Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32220181|t=2020. Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32286213|t=2020. Fatal outcome of coronavirus disease 2019 in a previously healthy 50-year-old man |pdf=|usr=}}
| |
| − | {{tp|p=32135586|t=2020. First case of severe childhood novel coronavirus pneumonia in China |pdf=|usr=}}
| |
| − | {{tp|p=32102141|t=2020. First case of 2019 novel coronavirus infection in children in Shanghai |pdf=|usr=}}
| |
| − | {{tp|p=32045966|t=2020. First case of severe childhood novel coronavirus pneumonia in China |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 222: |
Zeile 98: |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32270592|t=2020. Clinical characteristics of a case series of children with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32259403|t=2020. Novel coronavirus infection in children outside of Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32244248|t=2020. COVID-19 in children and altered inflammatory responses |pdf=|usr=}}
| |
| − | {{tp|p=32374856|t=ä. Characteristics of Doctors? Fatality due to COVID-19 in Western Europe and Asia-Pacific countries |pdf=|usr=}}
| |
| − | {{tp|p=32175637|t=ä. Clinical features of deaths in the novel coronavirus epidemic in China |pdf=|usr=}}
| |
| − | {{tp|p=32142398|t=2020. Patients with RT-PCR-confirmed COVID-19 and Normal Chest CT |pdf=|usr=}}
| |
| − | {{tp|p=32118389|t=2020. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China |pdf=|usr=}}
| |
| − | {{tp|p=32164091|t=2020. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing |pdf=|usr=}}
| |
| − | {{tp|p=32164090|t=2020. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32164089|t=2020. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32340095|t=2020. Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province |pdf=|usr=}}
| |
| − | {{tp|p=32120458|t=2020. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32377641|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − | {{tp|p=32377642|t=ä. Initial data from the COVID-19 Global Rheumatology Alliance provider registries ? Authors reply |pdf=|usr=}}
| |
| − | {{ttp|p=32374851|t=ä. The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance |pdf=|usr=}}
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32379296|t=2020. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32341581|t=2020. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials |pdf=|usr=}}
| |
| − | {{tp|p=32179860|t=2020. Don t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees |pdf=|usr=}}
| |
| − | {{tp|p=32349053|t=ä. Protection by Exclusion: Another Missed Opportunity to Include Pregnant Women in Research During the Coronavirus Disease 2019 (COVID-19) Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32369865|t=2020. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32333712|t=2020. SARS-CoV-2 pandemic and the need for transplant-oriented trials |pdf=|usr=}}
| |
| − | {{tp|p=32294824|t=2020. An urgent call for raising the scientific rigorousness of clinical trials on COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
| |
| − | {{tp|p=32297843|t=2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32380200|t=ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32275178|t=2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease |pdf=|usr=}}
| |
| − | {{tp|p=32216577|t=2020. Artificial intelligence and machine learning to fight COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380051|t=ä. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence |pdf=|usr=}}
| |
| − | {{tp|p=32352615|t=2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32209313|t=2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws |pdf=|usr=}}
| |
| − | {{tp|p=32285489|t=2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity |pdf=|usr=}}
| |
| − | {{tp|p=32267566|t=2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32267560|t=2020. Considerations for Statin Therapy in Patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32259313|t=2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32281114|t=2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient |pdf=|usr=}}
| |
| − | {{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32295694|t=2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG |pdf=|usr=}}
| |
| − | {{tp|p=32326830|t=2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management |pdf=|usr=}}
| |
| − | {{tp|p=32330404|t=2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32352594|t=2020. Phytotherapic compounds against coronaviruses: Possible streams for future research |pdf=|usr=}}
| |
| − | {{tp|p=32347602|t=2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32350134|t=2020. Effective treatment of severe COVID-19 patients with tocilizumab |pdf=|usr=}}
| |
| − | {{tp|p=32365207|t=ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report |pdf=|usr=}}
| |
| − | {{tp|p=32314850|t=2020. Melatonin: Roles in influenza, Covid?19, and other viral infections |pdf=|usr=}}
| |
| − | {{tp|p=32374874|t=ä. COVID-19: an unexpected indication for anti-rheumatic therapies?|pdf=|usr=}}
| |
| − | {{tp|p=32376603|t=ä. Development of an inactivated vaccine candidate for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32352871|t=2020. A Radiation Mitigator as a Potential Treatment for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32273254|t=2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32167254|t=2020. Epidemie de coronavirus et polemique sur la chloroquine |pdf=|usr=}}
| |
| − | {{tp|p=32270942|t=2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine |pdf=|usr=}}
| |
| − | {{tp|p=32301315|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2) |pdf=|usr=}}
| |
| − | {{tp|p=32301312|t=2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur |pdf=|usr=}}
| |
| − | {{tp|p=32355008|t=2020. COVID-19 shot protects monkeys |pdf=|usr=}}
| |
| − | {{tp|p=32292113|t=2020. Stem Cell?Based Therapy for Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32360327|t=ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence |pdf=|usr=}}
| |
| − | {{tp|p=32302280|t=2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department |pdf=|usr=}}
| |
| − | {{tp|p=32220178|t=2020. Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32374891|t=2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design |pdf=|usr=}}
| |
| − | {{tp|p=32374890|t=2020. COVID-19 convalescent plasma: phase 2 |pdf=|usr=}}
| |
| − | {{tp|p=32245869|t=2020. Possible treatment of Covid-19 with a therapeutic vaccine |pdf=|usr=}}
| |
| − | {{tp|p=32221001|t=2020. Possible method for the production of a Covid-19 vaccine |pdf=|usr=}}
| |
| − | {{tp|p=32324899|t=2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32319102|t=2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma |pdf=|usr=}}
| |
| − | {{tp|p=32240545|t=2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?|pdf=|usr=}}
| |
| − | {{tp|p=32268018|t=2020. Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining |pdf=|usr=}}
| |
| − | {{tp|p=32281335|t=2020. Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32281333|t=2020. Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32281332|t=2020. Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining |pdf=|usr=}}
| |
| − | {{tp|p=32281331|t=2020. Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32281330|t=2020. Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{ttp|p=32281329|t=2020. Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway |pdf=|usr=}}
| |
| − | {{tp|p=32281328|t=2020. Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP |pdf=|usr=}}
| |
| − | {{tp|p=32281327|t=2020. Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking |pdf=|usr=}}
| |
| − | {{tp|p=32164085|t=2020. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32164084|t=2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32164080|t=2020. Potential antiviral therapeutics for 2019 Novel Coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32164081|t=2020. Pharmacotherapeutics for the new coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32164077|t=2020. Pharmacotherapeutic about the new coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32114746|t=2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer |pdf=|usr=}}
| |
| − | {{tp|p=32234130|t=2020. Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32367576|t=2020. Saliva is a non-negligible factor in the spread of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32304466|t=2020. FECAL-ORAL TRANSMISSION OF SARS-COV-2 IN CHILDREN: IS IT TIME TO CHANGE OUR APPROACH?|pdf=|usr=}}
| |
| − | {{tp|p=32273447|t=2020. NAS letter suggests normal breathing can expel coronavirus |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Biophysics of aerosols]]''' |
| | | | |
| | | | |
| − | *'''[[Biophysics of aerosols]]'''
| |
| − | {{tp|p=32215590|t=2020. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32340022|t=2020. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals |pdf=|usr=}}
| |
| − | {{tp|p=32356927|t=2020. Consideration of the Aerosol Transmission for COVID-19 and Public Health |pdf=|usr=}}
| |
| − | {{tp|p=32171189|t=2020. Consideration and prevention for the aerosol transmission of 2019 novel coronavirus |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32320083|t=2020. Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports |pdf=|usr=}}
| |
| − | {{tp|p=32291807|t=2020. The importance of the minimum dosage necessary for UVC decontamination of N95 respirators during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32336079|t=2020. Medical mask or N95 respirator: When and how to use?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32372076|t=ä. SARS-CoV-2 human disinfection chambers: a critical analysis |pdf=|usr=}}
| |
| − | {{tp|p=32295880|t=2020. Inner Workings: Molecular biologists offer ?wartime service? in the effort to test for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32246121|t=2020. Safely conducting essential research in the face of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32380501|t=2020. Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg |pdf=|usr=}}
| |
| − | {{tp|p=32365049|t=2020. Tracheotomia az uj tipusu koronavirus okozta jarvany idejen(A COVID-19-pandemia orvosszakmai kerdesei) |pdf=|usr=}}
| |
| − | {{tp|p=32286909|t=2020. COVID-19 Pandemic: What Every Otolaryngologist-Head and Neck Surgeon Needs to Know for Safe Airway Management |pdf=|usr=}}
| |
| − | {{tp|p=32380508|t=2020. Neonatal emergency transport system during COVID-19 pandemic in the Veneto Region: proposal for standard operating procedures |pdf=|usr=}}
| |
| − | {{tp|p=32312176|t=2020. Peritoneal Dialysis in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364280|t=2020. The Role of Scientific Publishing in the SARS-CoV-2 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32371404|t=2020. Medical education during the COVID-19 pandemic: perspectives from UK trainees |pdf=|usr=}}
| |
| − | {{tp|p=32312755|t=2020. Impact of cancelling foundation year rotations due to the covid-19 outbreak in the UK |pdf=|usr=}}
| |
| − | {{tp|p=32277490|t=2020. SARS-CoV2 (COVID-19) infection: is fetal surgery in times of national disasters reasonable?|pdf=|usr=}}
| |
| − | {{tp|p=32376131|t=ä. LA PSIQUIATR�A EN LAS SECUELAS DE COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32125934|t=2020. Helping the Radiologist: The Role of Scientific Journals to Help Prevent the Spread of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32324100|t=2020. Imaging Publications in the COVID-19 Pandemic: Applying New Research Results to Clinical Practice |pdf=|usr=}}
| |
| − | {{tp|p=32216248|t=2020. Prevencion y control de la infeccion por coronavirus SARS-CoV-2 (Covid-19) en unidades de hemodialisis |pdf=|usr=}}
| |
| − | {{tp|p=32193300|t=2020. Coronavirus disruptions reverberate through research |pdf=|usr=}}
| |
| − | {{tp|p=32237972|t=2020. Impact of COVID-19 and Future Emerging Viruses on Hematopoietic Cell Transplantation and Other Cellular Therapies |pdf=|usr=}}
| |
| − | {{tp|p=32240543|t=ä. The impact of the SARS?CoV?2 outbreak on the safety and availability of blood transfusions in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32220180|t=2020. Oral Health Management of Children during the Epidemic Period of Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32310715|t=2020. Surgical Infection Society Guidance for Operative and Peri-Operative Care of Adult Patients Infected by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32096692|t=2020. Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32329654|t=2020. Telemedicine and e-Health Solutions for COVID-19: Patients Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32329659|t=2020. Role of Telehealth in the Management of COVID-19: Lessons Learned from Previous SARS, MERS, and Ebola Outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32324109|t=2020. Telemedicine During The COVID-19 in Italy: A Missed Opportunity?|pdf=|usr=}}
| |
| − | {{tp|p=32198754|t=2020. Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State |pdf=|usr=}}
| |
| − | {{tp|p=32280061|t=2020. COVID-19: Is a paradigm change to be expected in health care and transfusion medicine?|pdf=|usr=}}
| |
| − | {{tp|p=32361996|t=2020. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission |pdf=|usr=}}
| |
| − | {{tp|p=32357275|t=2020. Strategies for prevention and control of the 2019 novel coronavirus disease in the department of kidney transplantation |pdf=|usr=}}
| |
| − | {{tp|p=32348586|t=2020. How to guarantee liver transplantation in the north of Italy during the COVID-19 pandemic: A sound transplant protection strategy |pdf=|usr=}}
| |
| − | {{tp|p=32233049|t=2020. ISUOG Consensus Statement on organization of routine and specialist obstetric ultrasound services in context of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32267984|t=2020. ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32267981|t=2020. ISUOG Consensus Statement on rationalization of early-pregnancy care and provision of ultrasonography in context of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32255535|t=2020. ISUOG Safety Committee Position Statement on use of personal protective equipment and hazard mitigation in relation to SARS-CoV-2 for practitioners undertaking obstetric and gynecological ultrasound |pdf=|usr=}}
| |
| − | {{tp|p=32311760|t=2020. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment |pdf=|usr=}}
| |
| − | {{tp|p=32240537|t=2020. Post-donation COVID-19 identification in blood donors |pdf=|usr=}}
| |
| − | {{tp|p=32268712|t=2020. Perioperative management of cesarean section for pregnant women with suspected or confirmed COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32268711|t=2020. Systematic perinatal management of the pregnant women and neonates during the epidemic of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32268710|t=2020. Suggestions on delivery management of pregnant women with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32375428|t=2020. Protection suggestions on medical staff in obstetrics and gynecology in COVID-19-designated hospitals |pdf=|usr=}}
| |
| − | {{tp|p=32133829|t=2020. Analysis of bronchoscope-guided tracheal intubation in 12 cases with coronavirus disease 2019 under the personal protective equipment with positive pressure protective hood |pdf=|usr=}}
| |
| − | {{tp|p=32129580|t=2020. Expert consensus on pulmonary function testing during the epidemic of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32066206|t=2020. Countermeasures and treatment for aortic acute syndrome with novel coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32268640|t=2020. Technical guideline for disinfection of wastewater and wastes of medical organizations during COVID-19 outbreak |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32314806|t=2020. Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy |pdf=|usr=}}
| |
| − | {{tp|p=32340050|t=2020. Erfahrungen und Belastungserleben niedergelassener Neurologen und Psychiater wahrend der COVID-19-Pandemie |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32317306|t=2020. Increased Risk for Family Violence During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32380343|t=ä. Potential Threats of COVID-19 On Quarantined Families |pdf=|usr=}}
| |
| − | {{tp|p=32374894|t=2020. (Indoor) isolation, stress and physical inactivity: vicious circles accelerated by Covid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32273460|t=2020. Protecting older adults during social distancing |pdf=|usr=}}
| |
| − | {{tp|p=32364037|t=2020. The reproductive health fall-out of a global pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | | | |
| − | *'''[[Avoiding clinical medicine in other diseases]]'''
| |
| − | {{tp|p=32359403|t=ä. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands |pdf=|usr=}}
| |
| − | {{tp|p=32343497|t=ä. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − | {{tp|p=32299328|t=2020. Novel Coronavirus (COVID-19): What You Need to Know |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32377508|t=ä. Review on government action plans to reduce energy consumption in buildings amid COVID-19 pandemic outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32273610|t=2020. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future |pdf=|usr=}}
| |
| − | {{tp|p=32269308|t=2020. COVID-19 brings drug development to a halt |pdf=|usr=}}
| |
| − | {{tp|p=32284558|t=2020. How COVID-19 could ruin weather forecasts and climate records |pdf=|usr=}}
| |
| − | {{tp|p=32375016|t=2020. Workforce Survival: Tracking Potential COVID-19 Exposure Amid Socioeconomic Activities Using Automatic Log-Keeping Apps |pdf=|usr=}}
| |
| − | {{tp|p=32273444|t=2020. Pandemic brings mass vaccinations to a halt |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 439: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32380370|t=ä. COVID-19 pandemic: Impacts on the air quality during the partial lockdown in S�o Paulo state, Brazil |pdf=|usr=}}
| |
| − | {{tp|p=32298883|t=2020. Correlation between weather and Covid-19 pandemic in Jakarta, Indonesia |pdf=|usr=}}
| |
| − | {{tp|p=32217719|t=2020. COVID-19 drives new threat to bats in China |pdf=|usr=}}
| |
| − | {{tp|p=32273461|t=2020. Disinfection threatens aquatic ecosystems |pdf=|usr=}}
| |
| − | {{tp|p=32380152|t=ä. Potential infectious risk from the pets carrying SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32245870|t=2020. Can companion animals become infected with Covid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32221002|t=2020. Can companion animals become infected with Covid-19?|pdf=|usr=}}
| |
| − | {{tp|p=32343036|t=2020. Cats under the shadow of the SARS-CoV-2 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32303108|t=2020. Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals |pdf=|usr=}}
| |
| − | {{tp|p=32303151|t=2020. Can the human coronavirus epidemic also spread through solid waste?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32108071|t=2020. Where did SARS-CoV-2 come from?|pdf=|usr=}}
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32300018|t=2020. Demographic science aids in understanding the spread and fatality rates of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32218546|t=2020. What the cruise-ship outbreaks reveal about COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345687|t=2020. Sheltering in Place in a Xenophobic Climate: COVID-19 and Children in Immigrant Families |pdf=|usr=}}
| + | |
| − | {{tp|p=32179660|t=2020. Epidemiology of COVID-19 Among Children in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32356510|t=2020. Covid-19 and public health |pdf=|usr=}}
| + | |
| − | {{tp|p=32353901|t=2020. Rationale for universal face masks in public against COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32353723|t=2020. Early forecasting of the potential risk zones of COVID-19 in China s megacities |pdf=|usr=}}
| + | |
| − | {{tp|p=32304371|t=2020. Alfabetizacion en salud publica ante la emergencia de la pandemia por Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356896|t=2020. The COVID-19 (Coronavirus) pandemic: consequences for occupational health |pdf=|usr=}}
| + | |
| − | {{tp|p=32315842|t=2020. The international imperative to rapidly and inexpensively monitor community-wide Covid-19 infection status and trends |pdf=|usr=}}
| + | |
| − | {{tp|p=32332062|t=2020. Modeling infectious disease dynamics |pdf=|usr=}}
| + | |
| − | {{tp|p=32139521|t=2020. Can China s COVID-19 strategy work elsewhere?|pdf=|usr=}}
| + | |
| − | {{tp|p=32165563|t=2020. Airport screening is largely futile, research shows |pdf=|usr=}}
| + | |
| − | {{tp|p=32165562|t=2020. Genome analyses help track coronavirus moves |pdf=|usr=}}
| + | |
| − | {{tp|p=32299940|t=2020. Protect Indigenous peoples from COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32273446|t=2020. Can prophylactic drugs keep fragile health systems running?|pdf=|usr=}}
| + | |
| − | {{tp|p=32205458|t=2020. Aggregated mobility data could help fight COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32061201|t=2020. Cluster Investigation Technical Guideline for the 2019 Novel Coronavirus Pneumonia (COVID- 19), China (1st Trial Version) |pdf=|usr=}}
| + | |
| − | {{tp|p=32072794|t=2020. Cluster investigation Technical Guidelines for the 2019 Novel Coronavirus Pneumonia (COVID-19), China (1st Trial Version) |pdf=|usr=}}
| + | |
| − | {{tp|p=32064853|t=2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32057211|t=2020. An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32244261|t=2020. Comparison of two epidemic patterns of COVID-19 and evaluation of prevention and control effectiveness: an analysis based on Guangzhou and Wenzhou |pdf=|usr=}}
| + | |
| − | {{tp|p=32244260|t=2020. Epidemiological characteristics of COVID-19 in Shaanxi province |pdf=|usr=}}
| + | |
| − | {{tp|p=32340094|t=2020. Evaluation of the emergency response strategies and measures on the epidemic of COVID-19 in Shenzhen, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32340093|t=2020. Investigation on a cluster epidemic of COVID-19 in a supermarket in Liaocheng, Shandong province |pdf=|usr=}}
| + | |
| − | {{tp|p=32340092|t=2020. Suggestions on reforming and improving the prevention and treatment system for major epidemic diseases in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32340091|t=2020. Epidemic characteristics and trend analysis of the COVID-19 in Hubei province |pdf=|usr=}}
| + | |
| − | {{tp|p=32340090|t=2020. Discussion on early warning, prevention and control of emerging infectious diseases from a macroscopic perspective based on big data and effective distance model: enlightenment of COVID-19 epidemic data in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32312021|t=2020. Thoughts of the COVID-19 outbreak phases changed from emergency response to combination of emergency response and regular prevention and control |pdf=|usr=}}
| + | |
| − | {{tp|p=32274917|t=2020. Asymptomatic and pre-symptomatic cases of COVID-19 contribution to spreading the epidemic and need for targeted control strategies |pdf=|usr=}}
| + | |
| − | {{tp|p=32113198|t=2020. Fitting and forecasting the trend of COVID-19 by SEIR(+CAQ) dynamic model |pdf=|usr=}}
| + | |
| − | {{tp|p=32113196|t=2020. Study on assessing early epidemiological parameters of COVID-19 epidemic in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32113197|t=2020. Dynamic basic reproduction number based evaluation for current prevention and control of COVID-19 outbreak in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32234128|t=2020. Investigation of an epidemic cluster caused by COVID rectangle19 cases in incubation period in Shanghai |pdf=|usr=}}
| + | |
| − | {{tp|p=32234127|t=2020. Epidemiological characteristics of COVID-19 in Gansu province |pdf=|usr=}}
| + | |
| − | {{tp|p=32234126|t=2020. An epidemiologic thinking on the diagnosis criteria of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32125133|t=2020. Epidemic trend of corona virus disease 2019 (COVID-19) in mainland China |pdf=|usr=}}
| + | |
| − | {{tp|p=32125129|t=2020. Analysis on the epidemic factors for the Corona Virus Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32268644|t=2020. Transmission routes of 2019-novel coronavirus (2019-nCoV) |pdf=|usr=}}
| + | |
| − | {{tp|p=32268639|t=2020. Health protection guideline of hotels reconstructed as isolation places for close contacts during COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32268636|t=2020. Disinfection guideline of public transport during COVID-19 outbreak |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 501: |
Zeile 155: |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32296168|t=2020. Temporal dynamics in viral shedding and transmissibility of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32243729|t=ä. The isolation period should be longer: Lesson from a child infected with SARS?CoV?2 in Chongqing, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32379191|t=2020. Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan |pdf=|usr=}}
| + | |
| − | {{tp|p=32282658|t=2020. Rehospitalization of a Recovered Coronavirus Disease 19 (COVID-19) Child With Positive Nucleic Acid Detection |pdf=|usr=}}
| + | |
| − | {{tp|p=32356603|t=2020. Why the SARS-Cov-2 has prolonged spreading time in children?|pdf=|usr=}}
| + | |
| − | {{tp|p=32222122|t=2020. Follow-up testing of viral nucleic acid in discharged patients with moderate type of 2019 coronavirus disease (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32118391|t=2020. Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32352911|t=2020. COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment |pdf=|usr=}}
| |
| − | {{tp|p=32273583|t=2020. When COVID-19 meets centralized, personalized power |pdf=|usr=}}
| |
| − | {{tp|p=32217720|t=2020. Travel restrictions violate international law |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32371962|t=2020. Going viral: how to boost the spread of coronavirus science on social media |pdf=|usr=}}
| |
| − | {{tp|p=32377576|t=2020. Chatbots in the fight against the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32231320|t=2020. Blocking information on COVID-19 can fuel the spread of misinformation |pdf=|usr=}}
| |
| − | {{tp|p=32379194|t=2020. Demand for BCG Vaccine Due to Unproven Claims of its Role in Preventing COVID-19 Is Causing Shortages of Vaccines for Infants in Japan |pdf=|usr=}}
| |
| − | {{tp|p=32321859|t=2020. Twitter as a powerful tool for communication between pain physicians during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32198292|t=2020. Misguided drug advice for COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32317499|t=2020. A tribute to frontline corona warriors--Doctors who sacrificed their life while saving patients during the ongoing COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32238428|t=2020. Dr Li Wenliang and the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303602|t=2020. Letter to the Editor: Who was the first doctor to report the Covid-19 outbreak in Wuhan, China?|pdf=|usr=}}
| |
| − | {{tp|p=32310289|t=2020. Health Care Heroes of the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32049461|t=2020. Coronavirus : Dr Li Wenliang, lanceur d'alerte, heros et martyr |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| − | {{tp|p=32374357|t=2020. The Ethics of COVID-19 Immunity-Based Licenses ("Immunity Passports") |pdf=|usr=}}
| |
| − | {{tp|p=32380041|t=2020. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | ---- | | ---- |
| Zeile 547: |
Zeile 175: |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32364048|t=2020. The BMA COVID-19 ethical guidance: a legal analysis |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| − | {{tp|p=32349615|t=2020. COVID-19: A personal perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32371403|t=2020. A personal historical perspective of HIV |pdf=|usr=}}
| + | |
| − | {{tp|p=32355024|t=2020. Call for transparency of COVID-19 models |pdf=|usr=}}
| + | |
| − | {{tp|p=32217705|t=2020. Race to find COVID-19 treatments accelerates |pdf=|usr=}}
| + | |
| − | {{tp|p=32213646|t=2020. COVID-19 needs a big science approach|pdf=|usr=}}
| + | |
| − | {{tp|p=32054740|t=2020. Labs scramble to produce new coronavirus diagnostics |pdf=|usr=}}
| + | |
| − | {{tp|p=32241928|t=2020. Vaccine designers take first shots at COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32299994|t=2020. Vets would not manage Covid-19 this way |pdf=|usr=}}
| + | |
| − | {{tp|p=32187929|t=2020. 2019-nCoV: new challenges from coronavirus |pdf=|usr=}}
| + | |
| − | {{tp|p=32023682|t=2020. 2019-nCoV: new challenges from coronavirus |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | + | *'''[[Research tools]]''' |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32186279|t=2020. Facing challenges with the novel coronavirus SARS-CoV-2 outbreak |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| − | {{tp|p=32339250|t=2020. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019 |pdf=|usr=}} | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| − | {{tp|p=32275081|t=2020. Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles |pdf=|usr=}} | + | |
| − | {{tp|p=32365353|t=2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform |pdf=|usr=}}
| + | |
| − | {{tp|p=32349121|t=2020. Massively multiplexed nucleic acid detection with Cas13 |pdf=|usr=}}
| + | |
| − | | + | |
| | | | |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| − | {{tp|p=32108094|t=2020. Preprints bring firehose of outbreak data |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lunanano.com rna purfication]
| |
| − | *[sierramolecular.com rna safe sample collection]
| |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | *'''[[on-topic personal thoughts]]''' | | *'''[[on-topic personal thoughts]]''' |
